Cardiovascular Magnetic Resonance for Patients With COVID-19
(2022) In JACC: Cardiovascular Imaging 15(4). p.685-699- Abstract
COVID-19 is associated with myocardial injury caused by ischemia, inflammation, or myocarditis. Cardiovascular magnetic resonance (CMR) is the noninvasive reference standard for cardiac function, structure, and tissue composition. CMR is a potentially valuable diagnostic tool in patients with COVID-19 presenting with myocardial injury and evidence of cardiac dysfunction. Although COVID-19-related myocarditis is likely infrequent, COVID-19-related cardiovascular histopathology findings have been reported in up to 48% of patients, raising the concern for long-term myocardial injury. Studies to date report CMR abnormalities in 26% to 60% of hospitalized patients who have recovered from COVID-19, including functional impairment, myocardial... (More)
COVID-19 is associated with myocardial injury caused by ischemia, inflammation, or myocarditis. Cardiovascular magnetic resonance (CMR) is the noninvasive reference standard for cardiac function, structure, and tissue composition. CMR is a potentially valuable diagnostic tool in patients with COVID-19 presenting with myocardial injury and evidence of cardiac dysfunction. Although COVID-19-related myocarditis is likely infrequent, COVID-19-related cardiovascular histopathology findings have been reported in up to 48% of patients, raising the concern for long-term myocardial injury. Studies to date report CMR abnormalities in 26% to 60% of hospitalized patients who have recovered from COVID-19, including functional impairment, myocardial tissue abnormalities, late gadolinium enhancement, or pericardial abnormalities. In athletes post-COVID-19, CMR has detected myocarditis-like abnormalities. In children, multisystem inflammatory syndrome may occur 2 to 6 weeks after infection; associated myocarditis and coronary artery aneurysms are evaluable by CMR. At this time, our understanding of COVID-19-related cardiovascular involvement is incomplete, and multiple studies are planned to evaluate patients with COVID-19 using CMR. In this review, we summarize existing studies of CMR for patients with COVID-19 and present ongoing research. We also provide recommendations for clinical use of CMR for patients with acute symptoms or who are recovering from COVID-19.
(Less)
- author
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- in
- JACC: Cardiovascular Imaging
- volume
- 15
- issue
- 4
- pages
- 685 - 699
- publisher
- Elsevier
- external identifiers
-
- pmid:34656482
- scopus:85123513653
- ISSN
- 1876-7591
- DOI
- 10.1016/j.jcmg.2021.08.021
- language
- English
- LU publication?
- yes
- additional info
- Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.
- id
- 61a70d9b-111d-4eb8-be25-99c31da41aac
- date added to LUP
- 2022-03-16 11:07:59
- date last changed
- 2024-12-14 07:48:00
@article{61a70d9b-111d-4eb8-be25-99c31da41aac, abstract = {{<p>COVID-19 is associated with myocardial injury caused by ischemia, inflammation, or myocarditis. Cardiovascular magnetic resonance (CMR) is the noninvasive reference standard for cardiac function, structure, and tissue composition. CMR is a potentially valuable diagnostic tool in patients with COVID-19 presenting with myocardial injury and evidence of cardiac dysfunction. Although COVID-19-related myocarditis is likely infrequent, COVID-19-related cardiovascular histopathology findings have been reported in up to 48% of patients, raising the concern for long-term myocardial injury. Studies to date report CMR abnormalities in 26% to 60% of hospitalized patients who have recovered from COVID-19, including functional impairment, myocardial tissue abnormalities, late gadolinium enhancement, or pericardial abnormalities. In athletes post-COVID-19, CMR has detected myocarditis-like abnormalities. In children, multisystem inflammatory syndrome may occur 2 to 6 weeks after infection; associated myocarditis and coronary artery aneurysms are evaluable by CMR. At this time, our understanding of COVID-19-related cardiovascular involvement is incomplete, and multiple studies are planned to evaluate patients with COVID-19 using CMR. In this review, we summarize existing studies of CMR for patients with COVID-19 and present ongoing research. We also provide recommendations for clinical use of CMR for patients with acute symptoms or who are recovering from COVID-19.</p>}}, author = {{Petersen, Steffen E and Friedrich, Matthias G and Leiner, Tim and Elias, Matthew D and Ferreira, Vanessa M and Fenski, Maximilian and Flamm, Scott D and Fogel, Mark and Garg, Ria and Halushka, Marc K and Hays, Allison G and Kawel-Boehm, Nadine and Kramer, Christopher M and Nagel, Eike and Ntusi, Ntobeko A B and Ostenfeld, Ellen and Pennell, Dudley J and Raisi-Estabragh, Zahra and Reeder, Scott B and Rochitte, Carlos E and Starekova, Jitka and Suchá, Dominika and Tao, Qian and Schulz-Menger, Jeanette and Bluemke, David A}}, issn = {{1876-7591}}, language = {{eng}}, number = {{4}}, pages = {{685--699}}, publisher = {{Elsevier}}, series = {{JACC: Cardiovascular Imaging}}, title = {{Cardiovascular Magnetic Resonance for Patients With COVID-19}}, url = {{http://dx.doi.org/10.1016/j.jcmg.2021.08.021}}, doi = {{10.1016/j.jcmg.2021.08.021}}, volume = {{15}}, year = {{2022}}, }